Literature DB >> 12171219

Follow-up, treatment, and reinfection rates among asymptomatic chlamydia trachomatis cases in general practice.

Irene G M van Valkengoed1, Servaas A Morré, Adriaan J C van den Brule, Chris J L M Meijer, Lex M Bouter, Jacques Th M van Eijk, A Joan P Boeke.   

Abstract

BACKGROUND: Adequate treatment and follow-up of patients is essential to the success of a screening programme for Chlamydia trachomatis. There has been a lack of data on follow-up, confirmation of infections, and reinfection rates among asymptomatic patients in general practice. AIM: 7b study the rates of diagnostic confirmation of C trachomatis infection, successful treatment, and reinfection one year after cases were detected in a screening programme for asymptomatic infections. DESIGN OF STUDY: Prospective cohort study
SETTING: Fifteen general practices in Amsterdam, The Netherlands.
METHOD: One hundred and twenty-four patients with asymptomatic C trachomatis infections were requested to provide a cervical or urethral swab and a urine specimen, for the purpose of diagnostic confirmation before being treated. One year after the first screening, all of the patients were invited for a second screening. All samples were tested using the ligase chain reaction (Abbott Laboratories, Chicago, USA).
RESULTS: Out of 124 patients, 110 (89%) attended the scheduled appointment for diagnostic confirmation and treatment; 92 (84%) of them were confirmed to be positive and received treatment. At the second screening a year later, none of the 56 patients who had received treatment and who had been screened a second time were reinfected.
CONCLUSION: No asymptomatic patients werefound to have reinfections with C trachomatis one year after diagnostic confirmation and treatment. This underlines the effectiveness of the screening and treatment strategy

Entities:  

Mesh:

Year:  2002        PMID: 12171219      PMCID: PMC1314379     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  25 in total

1.  Performance and cost-effectiveness of selective screening criteria for Chlamydia trachomatis infection in women. Implications for a national Chlamydia control strategy.

Authors:  J M Marrazzo; C L Celum; S D Hillis; D Fine; S DeLisle; H H Handsfield
Journal:  Sex Transm Dis       Date:  1997-03       Impact factor: 2.830

2.  Molecular amplification assays to detect chlamydial infections in urine specimens from high school female students and to monitor the persistence of chlamydial DNA after therapy.

Authors:  C A Gaydos; K A Crotchfelt; M R Howell; S Kralian; P Hauptman; T C Quinn
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

3.  Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics. A cost-effectiveness analysis of three strategies.

Authors:  M R Howell; T C Quinn; C A Gaydos
Journal:  Ann Intern Med       Date:  1998-02-15       Impact factor: 25.391

4.  A multidistrict audit on the management of Chlamydia trachomatis in genitourinary medicine clinics in Yorkshire.

Authors:  E F Monteiro; J Harris; P Gilliatt
Journal:  Int J STD AIDS       Date:  1997-12       Impact factor: 1.359

5.  Diagnosis of urogenital Chlamydia trachomatis infection in women based on mailed samples obtained at home: multipractice comparative study.

Authors:  L Ostergaard; J K Møller; B Andersen; F Olesen
Journal:  BMJ       Date:  1996-11-09

6.  Incident Chlamydia trachomatis infections among inner-city adolescent females.

Authors:  G R Burstein; C A Gaydos; M Diener-West; M R Howell; J M Zenilman; T C Quinn
Journal:  JAMA       Date:  1998-08-12       Impact factor: 56.272

7.  Diagnosis of Chlamydia trachomatis infections in men and women by testing first-void urine by ligase chain reaction.

Authors:  M A Chernesky; D Jang; H Lee; J D Burczak; H Hu; J Sellors; S J Tomazic-Allen; J B Mahony
Journal:  J Clin Microbiol       Date:  1994-11       Impact factor: 5.948

8.  Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results.

Authors:  L Weström; R Joesoef; G Reynolds; A Hagdu; S E Thompson
Journal:  Sex Transm Dis       Date:  1992 Jul-Aug       Impact factor: 2.830

9.  Determinants of reinfection with Chlamydia trachomatis.

Authors:  C M Richey; M Macaluso; E W Hook
Journal:  Sex Transm Dis       Date:  1999-01       Impact factor: 2.830

10.  Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection.

Authors:  D Scholes; A Stergachis; F E Heidrich; H Andrilla; K K Holmes; W E Stamm
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

View more
  4 in total

1.  TLR2, TLR4 and TLR9 genotypes and haplotypes in the susceptibility to and clinical course of Chlamydia trachomatis infections in Dutch women.

Authors:  Stephan P Verweij; Ouafae Karimi; Jolein Pleijster; Joseph M Lyons; Henry J C de Vries; Jolande A Land; Servaas A Morré; Sander Ouburg
Journal:  Pathog Dis       Date:  2015-11-13       Impact factor: 3.166

2.  Acquired homotypic and heterotypic immunity against oculogenital Chlamydia trachomatis serovars following female genital tract infection in mice.

Authors:  Joseph M Lyons; Servaas A Morré; Lucy P Airo-Brown; A Salvador Peña; James I Ito
Journal:  BMC Infect Dis       Date:  2005-11-17       Impact factor: 3.090

3.  Efficacy of an immune modulator in experimental Chlamydia trachomatis infection of the female genital tract.

Authors:  Joseph M Lyons; James I Ito; Servaas A Morré
Journal:  Infect Dis Obstet Gynecol       Date:  2006

4.  Modelling the impact of chlamydia screening on the transmission of HIV among men who have sex with men.

Authors:  Maria Xiridou; Henrike J Vriend; Anna K Lugner; Jacco Wallinga; Johannes S Fennema; Jan M Prins; Suzanne E Geerlings; Bart J A Rijnders; Maria Prins; Henry J C de Vries; Maarten J Postma; Maaike G van Veen; Maarten F Schim van der Loeff; Marianne A B van der Sande
Journal:  BMC Infect Dis       Date:  2013-09-18       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.